Comparative Pharmacology
Head-to-head clinical analysis: AZOR versus DIUPRES 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZOR versus DIUPRES 250.
AZOR vs DIUPRES-250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, causing vasodilation and reduced peripheral vascular resistance. Olmesartan is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors, inhibiting vasoconstriction and aldosterone secretion.
Diupres-250 is a combination of hydrochlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water. Reserpine depletes catecholamines and serotonin from presynaptic nerve terminals by irreversibly binding to vesicular monoamine transporter (VMAT), leading to reduced sympathetic outflow and hypotension.
AZOR is a combination of amlodipine and olmesartan. Typical adult dose: one tablet orally once daily. Available strengths: amlodipine/olmesartan 5mg/20mg, 5mg/40mg, 10mg/20mg, 10mg/40mg. Dose can be titrated based on blood pressure response.
1 tablet (containing 250 mg chlorothiazide and 0.125 mg reserpine) orally once daily, increased to 2 tablets daily if needed.
None Documented
None Documented
Amlodipine: 30-50 h (terminal); supports once-daily dosing. Olmesartan: 10-15 h (terminal); once-daily dosing effective
Hydroflumethiazide: 6-18 hours (prolonged in renal impairment). Reserpine: 50-100 hours (biphasic; terminal phase).
Renal: 90% (amlodipine: 60% as metabolites, 10% as parent; olmesartan: 35-50% as parent via urine, rest in feces via bile). Fecal: 10%
Renal: approximately 50% of hydroflumethiazide is excreted unchanged in urine; reserpine is extensively metabolized with <1% excreted unchanged. Fecal: minimal.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination